Two companies are conducting trials to develop dengue vaccine, Director General, Indian Council of Medical Research Dr Rajeev Bahl told ANI on Tuesday.
According to the vaccine trials status, Panacea has done phase l/ll and the trials have been completed on 100 adults between the ages of 18 and 60 years.
The primary objective of the study is safety evaluation, immunogenicity, and viremia assessment. Now the company plans to start phase 3 randomised trials, double-blind, placebo-controlled trials on 10,335 healthy adults aged 18 to 80 yrs at 20 sites of the ICMR. These trials were approved in January 2023.
Speaking to ANI, Dr Bahl said, "The company which was supposed to make the products three months ago could not do so. However, now the company would be ready in August. So those trials will be initiated in phase three."
"Till now we can't say anything even about efficacy as well," he said further.
According to the presentation by ICMR during press briefing another company Serum Institute of India (SII) has completed phase one trials on 60 adults with the aim of safety evaluation.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Featured Video Of The Day
Bullseye! India's Homegrown Glide Bomb 'Gaurav' Hits Target 100 Km Away
Bharat Biotech Adds Top Medical Body ICMR As Co-Owner Of Covid Vaccine Patent Top Medical Body ICMR Warns Against Overcooking Dal, Saying It May Affect Nutritional Value Top Medical Body ICMR Advises People To Buy Whole Spices To Avoid Adulteration 2 French Rafale Jets Collide Mid-Air, Instructor, Pilot Missing Ayatollah Khamenei Warns Of "Divine Wrath" If Iran Backs Down Against Israel Cops Post Rioters' Pics After Vandalism During Kolkata Rape-Murder Protest In PM Modi's Independence Day Speech, A Call For "24x7 For 2047" Oropouche Virus Kills 2 In Brazil: All About The Rare Disease Punjab Toll Plaza Blunder: Man Charged Rs 220 While Relaxing At Home Track Latest News Live on NDTV.com and get news updates from India and around the world.